Skip to Content

Women with BRCA1 and BRCA2 mutations survive ovarian cancer at higher rates than those without mutations

Posted on January 24, 2012

Results from a National Cancer Institute (NCI) sponsored multi-center study published in the Journal of the American Medical Association on January 25, 2012, provides strong evidence that BRCA1 and BRCA2 gene mutation carriers with ovarian cancer were more likely to survive in the five years following diagnosis than were women with ovarian cancer who do not have mutations in these genes.

News Sources 

NCI News Note: Women with BRCA1 and BRCA2 mutations survive ovarian cancer at higher rates than those without mutations

The National Cancer Institute (NCI) press note on the study  

NCI Cancer Bulletin: Ovarian cancer patients with BRCA mutations may fare better than non-carriers

News article in NCI’s bi-weekly newsletter the Cancer Bulletin

DCEG Linkage: Scientific Highlight: BRCA1 and BRCA2 mutations

Short research highlight in the DCEG Linkage Newsletter

Information for Journalists

To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:

E-mail:
ncipressofficers@
mail.nih.gov

Phone: 301-496-6641